Stay updated with breaking news from Seth Wander. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC)
Seth Wander, MD, PhD, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial of lasofoxifene plus abemaciclib.
Durable responses with lasofoxifene plus abemaciclib in post-CDK4/6 inhibitor setting
/PRNewswire/ -- Regor Therapeutics Group ("Regor"), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development...
Oncology experts discuss the platinum chemotherapy shortage in the United States.